Clinical Trial Update: A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating the Dengue Tetravalent Vaccine (TDV) in adults aged 45-60 and 60-79, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dengue Fever

Drugs mentioned

• Dengue Tetravalent Vaccine (TDV) (Dengue tetravalent vaccine)

Snippet

Sponsor: Takeda | Conditions: Dengue Fever | Phase 3 | Status: RECRUITING